Arno Therapeutics, Inc.
ARNI
Rank in Stocks
#34676
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Share Price
$0.0001
Last synced: 2026-11-10
Market Cap
$4.47K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Arno Therapeutics, Inc. (ARNI)
Category
Healthcare
Operating Margin for Arno Therapeutics, Inc. (ARNI)
Operating Margin as of November 2026 TTM: 0.00%
According to Arno Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2015 the company had an operating margin of 0.00%.
Operating Margin history for Arno Therapeutics, Inc. from 2003 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | -100.00% |
| 2005 | -838.82% | -63.99% |
| 2004 | -2,329.48% | 0.00% |
| 2003 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Arno Therapeutics, Inc.'s operating margin
What was Arno Therapeutics, Inc.'s operating margin in 2015?
In 2015, Arno Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2014.
How has Arno Therapeutics, Inc.'s operating margin changed since 2010?
From 2010 to 2015, Arno Therapeutics, Inc.'s operating margin was highest in 2015 (0.00%) and lowest in 2015 (0.00%).
How does Arno Therapeutics, Inc.'s operating margin compare with similar companies?
Arno Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.